Periprocedural antithrombotic strategies in acute coronary syndromes undergoing percutaneous coronary intervention: Have we discarded bivalirudin too soon?
S Benenati, GL De Maria, F Della Mora… - Cardiovascular …, 2023 - Elsevier
Background Publication of the BRIGHT-4 trial results has restimulated discussion about the
optimal periprocedural antithrombotic strategy for patients undergoing percutaneous …
optimal periprocedural antithrombotic strategy for patients undergoing percutaneous …
Periprocedural antithrombotic strategies in acute coronary syndromes undergoing percutaneous coronary intervention: Have we discarded bivalirudin too soon?
S Benenati, GL De Maria, FD Mora… - Cardiovascular …, 2023 - europepmc.org
Background Publication of the BRIGHT-4 trial results has restimulated discussion about the
optimal periprocedural antithrombotic strategy for patients undergoing percutaneous …
optimal periprocedural antithrombotic strategy for patients undergoing percutaneous …
Periprocedural antithrombotic strategies in acute coronary syndromes undergoing percutaneous coronary intervention: Have we discarded bivalirudin too soon?
S Benenati, GL De Maria… - Cardiovascular …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Publication of the BRIGHT-4 trial results has restimulated discussion about the
optimal periprocedural antithrombotic strategy for patients undergoing percutaneous …
optimal periprocedural antithrombotic strategy for patients undergoing percutaneous …